期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

晚期卵巢癌的巩固或维持治疗 被引量：3

Consolidation or maintenance therapy for advanced ovarian cancer
原文传递
导出
摘要 对初次标准治疗后达到完全缓解的卵巢癌患者给予巩固治疗或维持治疗,可以延缓复发.巩固或维持治疗的方案有化疗、放疗及生物治疗.临床试验证实,上述治疗方案各有优缺点,临床疗效也不尽相同.目前学者还在寻找新的巩固治疗方案,为延缓或预防卵巢癌复发提供最佳治疗途径. Consolidation therapy or maintenance therapy for complete response to conventional treatment can delay recurrence of ovarian cancer.Consolidation or maintenance therapy programs include chemotherapy,radiotherapy and biological treatment.Clinical trials confirm that these treatment agents have their advantages and disadvantages,and the effects are quite different.Now scientists are still exploring new agents,for finding the best pathway to delay or even prevent recurrence.
作者 夏婷 于爱军
机构地区 浙江省肿瘤医院妇瘤科
出处 《国际肿瘤学杂志》 CAS 2014年第1期60-62,共3页 Journal of International Oncology
关键词 卵巢肿瘤 治疗结果 巩固治疗 Ovarian neoplasms Treatment outcome Consolidation therapy
分类号 R737.31 [医药卫生—肿瘤]
  • 相关文献

参考文献10

  • 1Ozols RF. Maintenance therapy in advanced ovarian cancer: progressionfree survival and clinical benefit[J].J Clin Oncol.2003, 21(13):2451-2453.
  • 2Markman M, Liu PY, Wilczynski S, et al. Phase Ⅲ randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxelbased chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group Trial[J].J Clin Oncol.2003, 21(13):2460-2465.
  • 3Markman M, Liu PY, Moon J, et al. Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinumpaclitaxel: followup of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial[J].Gynecol Oncol.2009, 114(2):195-198.
  • 4Pecorelli S, Favalli G, Gadducci A, et al. Phase Ⅲ trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinumbased chemotherapy: final results of the after6 protocol 1[J].J Clin Oncol.2009, 27(28):4642-4648.
  • 5De Placido S, Scambia G, Di Vagno G, et al. Topotecan compared with no therapy after response to surgery and carboplatin/paelitaxel in patients with ovarian cancer: multicenter italian trials in ovarian cancer (M1TO1) randomized study[J].J Clin Oncol.2004, 22(13):2635-2642.
  • 6Kim JH, Lee JM, Ryu KS, et al. Consolidation hyperthermic intraperitoneal chemotherapy using paclitaxel in patients with epithelial ovarian cancer[J]. J Surg Oncol, 2010, 101(2):149155.
  • 7Sorbe B. Consolidation treatment of advanced ovarian carcinoma with radiotherapy after induction chemotherapy[J]. Int J Gynecol Cancer, 2003, 13 Suppl 2:192195.
  • 8Berek J, Taylor P, McGuire W, et al. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cance[J]. J Clin Oncol, 2009, 27(3):418425.
  • 9Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primarytreatment of ovarian cancer[J]. N Engl J Med, 2011, 365(26):24732483.
  • 10Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer[J].N Engl J Med.2011, 365(26):2484-2496.

同被引文献60

  • 1Li Yifan,Li Juan,Fan Bifa,Wang Yitong,Jiang Juling,Zhang Zhenhua,Wang Xinxing,Lu Wenping.Efficacy and safety of Yiqi Huoxue Jiedu decoction for the treatment of advanced epithelial ovarian cancer patients: a double-blind randomized controlled clinical trial[J].Journal of Traditional Chinese Medicine,2020,40(1):103-111. 被引量：12
  • 2夏霁,颜梦宇,韩凤娟.卵巢癌中西医结合多学科综合协作诊疗模式新探索[J].上海中医药杂志,2020,54(1):5-8. 被引量：9
  • 3Otis - Green S, Wakabayashi MT, Morgan R, et al. Palliative Care Op- portunities for Women with Advanced Ovarian Cancer Associated with In- traperitoneal Chemotherapy[J] .Journal of palliative medicine, 2013, 16(1):44-53.
  • 4Bamias A, Bamia C, Zagouri F, et al. Improved survival trends in plat- inum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first -line paclitaxel/platinum chemotherapy:the im- pact of novel agents[J]. Oncology,2012,84(3) : 158 - 165.
  • 5Chambers SK,Chow HS,Janicek MF,et al. Phase I trim of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian can- cer[J]. Clinical Cancer Research,2012,18(9) :2 668 -2 678.
  • 6Hoskins P, Vergote I, Cervantes A, et al. Advanced ovarian cancer: phase Ⅲ randomized study of sequential cisplatin topotecan and carboplatin pa- clitaxel vs carboplatin paclitaxel [ J]. Journal of the National Cancer Insti- tute,2010,102(20) : 1 547 - 1 556.
  • 7Moon JH, Lee HJ, Kang WD, et al. Prognostic value of serum CA - 125 in patients with advanced epithelial ovarian cancer followed by complete re- mission after adjuvant chemotherapy[J]. Obstetrics & gynecology sci- ence,2013,56(1) :29 -35.
  • 8Furukawa N, Sasaki Y, Shigemitsu A, et al. CA - 125 cut -off value as a predictor for complete interval debulking surgery after neoadjuvant chemotherapy in patients with advanced ovarian cancer[J]. Journal of gy- necologic oneology. 2013.24 (2): 141 - 145.
  • 9Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010[J]. CACancer J Clin, 2010, 60(5): 277-300. DOI: 10. 3322/eaac. 20073.
  • 10Fayers P, Bottomley A, EORTC Quality of Life Group, et al, Quality of life research within the EORTC-the EORTC QLQ-C30. European Organisation for Research and Treatment of Cancer[ J]. Eur J Can- cer, 2002, 38 Suppl 4: S125-133.

引证文献3

二级引证文献13

国际肿瘤学杂志
2014年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部